Further evidence that behavioral tests and neuropeptide mRNA and tissue level alterations can differentiate between typical and atypical antipsychotic drugs

Neuropsychopharmacology

Volumn 23, Issue 1, 2000, Pages 46-55

  Bauer, Richard ^a   Mayr, Adelcy ^b   Lederer, Wolfgang ^b   Needham, Patricia L ^c   Kilpatrick, Ian C ^c   Fleischhacker, Wolfgang W ^b   Marksteiner, Josef ^a  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^b UNIVERSITY OF INNSBRUCK   (Austria)

^c ABBOTT LABORATORIES   (United States)

Author keywords

Antipsychotic drugs; Chromogranins; Gene expression; Neuropeptides

Indexed keywords

CHROMOGRANIN A; CHROMOGRANIN B; CLOZAPINE; ENKEPHALIN; HALOPERIDOL; MESSENGER RNA; NEUROLEPTIC AGENT; NEUROPEPTIDE; RISPERIDONE; SECRETOGRANIN II; ZOTEPINE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BEHAVIOR; CATALEPSY; CONTROLLED STUDY; DRUG CLASSIFICATION; GENE EXPRESSION; IN SITU HYBRIDIZATION; MALE; NONHUMAN; PREFRONTAL CORTEX; PRIORITY JOURNAL; PROTEIN SYNTHESIS; PSYCHOSIS; PUTAMEN; RADIOIMMUNOASSAY; RAT;

ANIMALS; ANTIPSYCHOTIC AGENTS; BEHAVIOR, ANIMAL; CATALEPSY; CAUDATE NUCLEUS; MALE; NEUROPEPTIDES; PREFRONTAL CORTEX; PUTAMEN; RATS; RATS, SPRAGUE-DAWLEY; RNA, MESSENGER;

EID: 0034086899     PISSN: 0893133X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0893-133X(00)00086-5     Document Type: Article

References (50)

1. Angulo J.A. Involvement of dopamine D1 and D2 receptors in the regulation of proenkephalin mRNA abundance in the striatum and accumbens of the rat brain. J Neurochem. 58:1992;110-1109.
2. Arnt J., Skarsfeldt T. Do novel antipsychotics have similar pharmacological characteristics? A review of the evidence. Neuropsychopharmacology. 18:1998;63-101.
3. Atkins J.B., Chlan-Fourney J., Nye H.E., Hiroi N., Carlezon W.A., Nestler E.J. Region-specific induction of deltaFosB by repeated administration of typical versus atypical antipsychotic drugs. Synapse. 33:1999;118-128.
4. Augood S.J., Westmore K., Faull R.L., Emson P.C. Neuroleptics and striatal neuropeptide gene expression. Prog Brain Res. 99:1993;181-199.
5. Chanat E., Weiss U., Huttner W.B., Tooze S.A. Reduction of the disulfide bond of chromogranin B (secretogranin I) in the trans-Golgi network causes its missorting to the constitutive secretory pathways. EMBO J. 12:1993;2159-2168.
6. Comb M., Seeburg P.H., Adelman J., Eiden L., Herbert E. Primary structure of the human met- and leu-enkephaline precursor of its mRNA. Nature. 295:1982;663-666.
7. Deutch A.Y., Duman R.S. The effects of antipsychotic drugs on Fos protein expression in the prefrontal cortex. Cellular localization and pharmacological characterization Neuroscience. 70:1996;377-389.
8. Ellenbroek B., Cools A.R. The Paw Test. An animal model for neuroleptic drugs which fulfils the criteria for pharmacological isomorphism Life Sci. 42:1988;1205-1213.
9. Ellenbroek B.A., Prinssen E.P., Cools A.R. The role of serotonin receptor subtypes in the behavioural effects of neuroleptic drugs. A paw test study in rats. Eur J Neurosci. 6:1994;1-8.
10. Ezrin W.C., Seeman P. Tolerance of haloperidol catalepsy. Eur J Pharmacol. 41:1977;321-327.
11. Fleischhacker W.W., Hummer M. Drug treatment of schizophrenia in the 1990s. Achievements and future possibilities in optimising outcomes. Drugs. 53:1997;915-929.
12. Forss P.S., Danielson P., Battenberg E., Bloom F., Sutcliffe J.G. Nucleotide sequence and cellular distribution of rat chromogranin B (secretogranin I) mRNA in the neuroendocrine system. J Mol Neurosci. 1:1989;63-75.
13. Gerdes H.H., Phillips E., Huttner W.B. The primary structure of rat secretogranin II deduced from a cDNA sequence. Nucl Ac Res. 16:1988;11811.
14. Guo N., Vincent S.R., Fibiger H.C. Phenotypic characterization of neuroleptic-sensitive neurons in the forebrain. Contrasting targets of haloperidol and clozapine Neuropsychopharmacology. 19:1998;133-145.
15. Herman Z.S., Huzarska M., Kmieciak K.K., Kowalski J. Chronic treatment with chlorpromazine, thioridazine or haloperidol increases striatal enkephalins and their release from rat brain. Psychopharmacology (Berl). 104:1991;106-112.
16. Hiroi N., Graybiel A.M. Atypical and typical neuroleptic treatments induce distinct programs of transcription factor expression in the stratium. J Comp Neurol. 374:1996;70-83.
17. Huttner W.B., Gerdes H.H., Rosa P. The granin (chromogranin/secretogranin) family. TIBS. 16:1991;27-30.
18. Hyman S.E., Nestler E.J. Initiation and adaptation. A paradigm for understanding psychotropic drug action Am J Psychiatry. 153:1996;151-162.
19. Iacangelo A., Okayama H., Eiden L.E. Primary structure of rat chromogranin A and distribution of its mRNA. FEBS Lett. 227:1988;115-121.
20. Ichikawa J., Kuroki T., Dai J., Meltzer H.Y. Effect of antipsychotic drugs on extracellular serotonin levels in rat medial prefrontal cortex and nucleus accumbens. Eur J Pharmacol. 351:1998;163-171.
21. Kirchmair R., Hogue-Angeletti R., Gutierrez J., Fischer-Colbrie R., Winkler H. Secretoneurin - a neuropeptide generated in brain, adrenal medulla and other endocrine tissues by proteolytic processing of secretogranin II (chromogranin C). Neuroscience. 53:1993;359-365.
22. Knable M.B., Weinberger D.R. Dopamine, the prefrontal cortex and schizophrenia. J Psychopharmacol. 11:1997;123-131.
23. Kroesen S., Marksteiner J., Leitner B., Hogue Angeletti R., Fischer Colbrie R., Winkler H. Rat brain. distribution of immunoreactivity of PE-11, a peptide derived from chromogranin B Eur J Neurosci. 8:1996;2679-2689.
24. Kroesen S., Marksteiner J., Mahata S.K., Mahata M., Fischer Colbrie R., Saria A., Kapeller I., Winkler H. Effects of haloperidol, clozapine and citalopram on messenger RNA levels of chromogranins A and B and secretogranin II in various regions of rat brain. Neuroscience. 69:1995;881-891.
25. Le Moine C., Normand E., Bloch B. Phenotypical characterization of the rat striatal neurons expressing the D1 dopamine receptor gene. Proc Natl Acad Sci USA. 88:1991;4205-4209.
26. Leysen J.E., Janssen P.M., Schotte A., Luyten W.H., Megens A.A. Interaction of antipsychotic drugs with neurotransmitter receptor sites in vitro and in vivo in relation to pharmacological and clinical effects. Role of 5HT2 receptors Psychopharmacology (Berl). 112:1993;S40-S54.
27. Lieberman J.A., Sheitman B.B., Kinon B.J. Neurochemical sensitization in the pathophysiology of schizophrenia. Deficits and dysfunction in neuronal regulation and plasticity Neuropsychopharmacology. 17:1997;205-229.
28. MacArthur L., Eiden L. Neuropeptide genes. targets of activity-dependent signal transduction Peptides. 17:1996;721-728.
29. Mahata S.K., Mahata M., Marksteiner J., Sperk G., Fischer-Colbrie R., Winkler H. Distribution of mRNAs for chromogranin A and B and secretogranin II in rat brain. Eur J Neurosci. 3:1991;895-904.
30. Mahata S.K., Mahata M., Parmer R.J., O'Connor D.T. Desensitization of catecholamine release. The novel catecholamine release-inhibitory peptide catestatin (chromogranin a344-364) acts at the receptor to prevent nicotinic cholinergic tolerance. J Biol Chem. 274:1999;2920-2928.
31. Marin C., Engber T.M., Bonastre M., Chase T.N., Tolosa E. Effect of long-term haloperidol treatment on striatal neuropeptides. Relation to stereotyped behavior Brain Res. 731:1996;57-62.
32. Marksteiner J., Kirchmair R., Mahata S.K., Mahata M., Fischer-Colbrie R., Hogue-Angeletti R., Saria A., Winkler H. Distribution of secretoneurin, a peptide derived from secretogranin II, in rat brain. An immunocytochemical and radioimmunological study Neuroscience. 54:1993;923-944. a.
33. Marksteiner J., Saria A., Miller C.H., Krause J.E. Increased synthesis of neurokinin B and enkephalin after chronic haloperidol treatment. Regul Pept. 46:1993;349-351. b.
34. Marksteiner J., Sperk G. Concomitant increase of somatostatin, neuropeptide Y and glutamate decarboxylase in the frontal cortex of rats with decreased seizure threshold. Neuroscience. 26:1988;379-385.
35. Mercugliano M., Chesselet M.F. Clozapine decreases enkephalin mRNA in rat striatum. Neurosci Lett. 136:1992;10-14.
36. Mijnster M.J., Ingham C.A., Meredith G.E., Docter G.J., Arbuthnott G.W. Morphological changes in met(5)-enkephalin-immunoreactive synaptic boutons in the rat neostriatum after haloperidol decanoate treatment. Eur J Neurosci. 8:1996;716-726.
37. Mijnster M.J., Schotte A., Docter G.J., Voorn P. Effects of risperidone and haloperidol on tachykinin and opioid precursor peptide mRNA levels in the caudate-putamen and nucleus accumbens of the rat. Synapse. 28:1998;302-312.
38. Needham P.L., Atkinson J., Skill M.J., Heal D.J. Zotepine. Preclinical tests predict antipsychotic efficacy and an atypical profile Psychopharmacol Bull. 32:1996;123-128.
39. Nguyen T.V., Kosofsky B.E., Birnbaum R., Cohen B.M., Hyman S.E. Differential expression of c-Fos and Zif268 in rat striatum after haloperidol, clozapine, and amphetamine. Proc Natl Acad Sci USA. 89:1992;4270-4274.
40. Normand E., Popovici T., Fellmann D., Bloch B. Anatomical study of enkephalin gene expression in the rat forebrain following haloperidol treatment. Neurosci Lett. 83:1987;232-236.
41. O'Donnell P., Grace A.A. Dysfunctions in multiple interrelated systems as the neurobiological bases of schizophrenic symptom clusters. Schizophr Bull. 24:1998;267-283.
42. Paxinos G., Watson C. The rat brain in stereotaxic coordinates. 2nd ed:1986;Academic Press, Sydney.
43. Robertson G.S., Fibiger H.C. Neuroleptics increase c-fos expression in the forebrain. Contrasting effects of haloperidol and clozapine Neuroscience. 46:1992;315-328.
44. Robertson G.S., Fibiger H.C. Effects of olanzapine on regional C-Fos expression in rat forebrain. Neuropsychopharmacology. 14:1996;105-110.
45. Robertson G.S., Matsumura H., Fibiger H.C. Induction patterns of Fos-like immunoreactivity in the forebrain as predictors of atypical antipsychotic activity. J Pharmacol Exp Ther. 271:1994;1058-1066.
46. Romano G.J., Shivers B.D., Harlan R.E., Howells R.D., Pfaff D.W. Haloperidol increases proenkephalin mRNA levels in the caudate-putamen of the rat. A quantitative study at the cellular level using in situ hybridization Brain Res. 388:1987;33-41.
47. Schotte A., Janssen P.F., Gommeren W., Luyten W.H., Van G.P., Lesage A.S., De L.K., Leysen J.E. Risperidone compared with new and reference antipsychotic drugs. In vitro and in vivo receptor binding Psychopharmacology (Berl). 124:1996;57-73.
48. Selemon L.D., Goldman-Rakic P.S. The reduced neuropil hypothesis. A circuit based model of schizophrenia Biol Psychiatry. 45:1999;17-25.
49. Shen P.J., Gundlach A.L. Chromogranin mRNA levels in the brain as a marker for acute and chronic changes in neuronal activity. Effect of treatments including seizures, osmotic stimulation and axotomy in the rat Eur J Neurosci. 8:1996;988-1000.
50. Thiele C., Huttner W.B. The disulfide-bonded loop of chromogranins, which is essential for sorting to secretory granules, mediates homodimerization. J Biol Chem. 273:1998;1223-1231.